Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Treasury Shares (2020 - 2025)

Historic Treasury Shares for Mereo BioPharma (MREO) over the last 4 years, with Q4 2023 value amounting to $1.2 million.

  • Mereo BioPharma's Treasury Shares fell 786.52% to $1.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.2 million, marking a year-over-year decrease of 786.52%. This contributed to the annual value of $1.2 million for FY2023, which is 786.52% down from last year.
  • Mereo BioPharma's Treasury Shares amounted to $979608.0 in Q3 2025, which was up 1452.38% from $979608.0 recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma's Treasury Shares peaked at $1.3 million during Q1 2024, and registered a low of $855375.0 during Q2 2024.
  • Moreover, its 3-year median value for Treasury Shares was $951504.0 (2023), whereas its average is $970812.4.
  • As far as peak fluctuations go, Mereo BioPharma's Treasury Shares plummeted by 1312.73% in 2022, and later plummeted by 786.52% in 2023.
  • Mereo BioPharma's Treasury Shares (Quarter) stood at $1.7 million in 2020, then dropped by 10.82% to $1.5 million in 2021, then fell by 13.13% to $1.3 million in 2022, then fell by 7.87% to $1.2 million in 2023.
  • Its Treasury Shares stands at $1.2 million for Q4 2023, versus $1.3 million for Q4 2022 and $1.5 million for Q4 2021.